Get the Stockscreener App
476.90
1.63%
7.63
After Hours:
475.00
-1.90
-0.40%
Vertex Pharmaceuticals Inc stock is traded at $476.90, with a volume of 1.01M.
It is up +1.63% in the last 24 hours and up +7.88% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$469.27
Open:
$466.94
24h Volume:
1.01M
Relative Volume:
0.70
Market Cap:
$121.15B
Revenue:
$12.07B
Net Income/Loss:
$3.95B
P/E Ratio:
31.10
EPS:
15.3349
Net Cash Flow:
$3.19B
1W Performance:
-2.96%
1M Performance:
+7.88%
6M Performance:
+20.93%
1Y Performance:
-0.71%
1-Day Range:
$465.00
$479.12
1-Week Range:
$463.00
$494.05
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? - Nasdaq
Tredje AP fonden Sells 65,290 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Mitsubishi UFJ Asset Management UK Ltd. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jupiter Asset Management Ltd. Invests $25.70 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows - Investing.com
HighTower Advisors LLC Sells 12,332 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash - AOL.com
Is Vertex Pharmaceuticals (VRTX) Now Offering A Compelling Entry Point After Flat One Year Returns - Yahoo Finance
Insider Sell: Atkinson Edward Morrow III Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Broadens Beyond Cystic Fibrosis As CASGEVY And Pipeline Take Shape - Yahoo Finance
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Mcrae Capital Management Inc. Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Cumberland Partners Ltd Has $3.82 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Q4 2025 Earnings: Revenue Beats, Driven by CF Growth & New LaunchesNews and Statistics - IndexBox
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q4 Earnings Call - Finviz
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call - TradingView
Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells 1,500 Shares of Stock - MarketBeat
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade) (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Canaccord G - GuruFocus
Grange Capital LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
PNC Financial Services Group Inc. Has $27.33 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals stock: Is Wall Street bullish or bearish? - MSN
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - PharmiWeb.com
Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks - MSN
Narrow-Moat Vertex's Strong CF Sales Drive Growth as Non-CF Portfolio Starts to Gain Traction - Morningstar
Vertex CEO to discuss strategy at TD Cowen health care conference - Stock Titan
Vertex Pharmaceuticals (VRTX) Sees Analyst Rating Maintained wit - GuruFocus
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - Yahoo Finance
HC Wainwright & Co. Raises Vertex Pharmaceuticals (VRTX) Price Target | VRTX Stock News - GuruFocus
Vanguard Group Inc. Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
NEOS Investment Management LLC Purchases 37,296 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Skandinaviska Enskilda Banken AB publ Has $60.39 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Public Sector Pension Investment Board Has $8.78 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Top-Rated Stocks: Vertex Pharmaceuticals Sees Composite Rating Climb To 96 - Investor's Business Daily
Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Oppenheimer Upgrades Vertex Pharmaceuticals (VRTX) - Nasdaq
Zions Bancorporation National Association UT Buys 9,452 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by State of New Jersey Common Pension Fund D - MarketBeat
Cibc World Market Inc. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 6.93% Upside Potential - DirectorsTalk Interviews
Vertex’s Journavx Surpasses Half a Million Prescriptions Amid Biopharma Sector Developments - geneonline.com
1 reason I'd buy Vertex Pharmaceuticals stock and never sell - MSN
Promising Biotech Stocks To Add to Your WatchlistFebruary 15th - MarketBeat
Shell Asset Management Co. Sells 10,515 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Prospera Financial Services Inc Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Aberdeen Group plc - MarketBeat
ABN Amro Investment Solutions Has $49.33 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story - Yahoo! Finance Canada
Assetmark Inc. Decreases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Ins - GuruFocus
Vertex Pharmaceuticals (VRTX) Receives Boosted Price Target from HC Wainwright & Co. | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):